Fibroblast Growth Factor 21 Levels and Bone Mineral Density in Metabolically Healthy and Metabolically Unhealthy Obese Children

Autor: Akduman F; Ankara University Faculty of Medicine, Department of Pediatrics, Ankara, Turkey, Şıklar Z; Ankara University Faculty of Medicine, Department of Pediatric Endocrinology, Ankara, Turkey, Özsu E; Ankara University Faculty of Medicine, Department of Pediatric Endocrinology, Ankara, Turkey, Doğan Ö; Ankara University Faculty of Medicine, Department of Clinical Biochemistry, Ankara, Turkey, Kır MK; Ankara University School of Medicine, Department of Nuclear Medicine, Ankara, Turkey, Berberoğlu M; Ankara University Faculty of Medicine, Department of Pediatric Endocrinology, Ankara, Turkey
Jazyk: angličtina
Zdroj: Journal of clinical research in pediatric endocrinology [J Clin Res Pediatr Endocrinol] 2022 Dec 01; Vol. 14 (4), pp. 433-443. Date of Electronic Publication: 2022 Jul 21.
DOI: 10.4274/jcrpe.galenos.2022.2022-1-15
Abstrakt: Objective: The harmful or beneficial effect of obesity on bone mineral density (BMD) remains controversial in children and adolescents. Fibroblast growth factor 21 (FGF21) is a metabolic factor that plays a specific role in the regulation of carbohydrate and lipid metabolism. However, the role of FGF21 in bone metabolism appears paradoxical and is complex. To determine whether serum FGF21 level was associated with BMD in obese children and adolescents.
Methods: The study was conducted with the participation of children and adolescents aged 8-18 years. Ninety-eight obese children were included in the study group and 44 children were included in the control group. BMD, in addition to the routine obesity workup, which includes fasting blood glucose, fasting insulin levels, lipid profile, and liver enzymes; serum FGF21 levels have been analyzed.
Results: The mean age of the obese group (n=98) was 13.34±2.24 years and the mean age of controls (n=44) was 13.48±2.87 years. Based on International Diabetes Federation criteria, 15 of 98 (15.3%) patients were metabolically unhealthy. FGF21 levels were 193.54±139.62 mg/dL in the obese group and 158.69±151.81 mg/dL in the control group (p=0.06). There was no difference between the FGF21 and BMD z-score values of girls and boys in the obese and control groups (p>0.05).
Conclusion: BMD-z-score was increased in obese children compared to healthy control. Moreover, BMD-z-score tended to be higher when more metabolic risk factors were present. However, there was no significant relationship between FGF21 levels and BMD z-score values in obese children.
Databáze: MEDLINE
Externí odkaz: